In order to investigate whether malignant growth of MM cells might be affected by pharmacologic HUWE1 inhibition, we treated HMCLs (Fig. 2a), primary MM cells and normal mononuclear cells from peripheral blood (PBMCs; Fig. 2b) with 10 μM BI8622 for 48 h prior to viability analysis by MTT assay (HMCLs) or annexin V/PI staining and FACS measurement (primary MM cells and PBMCs). The gene discussed is HUWE1; the disease is Miyoshi myopathy.